Intended for healthcare professionals


EU to provide incentives for “orphan” drugs

BMJ 2000; 320 doi: (Published 13 May 2000) Cite this as: BMJ 2000;320:1294
  1. Rory Watson
  1. Brussels

    The European Union has introduced new legislation designed to encourage pharmaceutical companies to develop treatments for “orphan” (rare)diseases that affect fewer than five people in every 10000 within the 15 member bloc.

    Since the beginning of this month companies have been able to apply to the London based European Agency for the Evaluation of Medicinal Products …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription